GENFLEET-B (02595) Jumps Nearly 4% in Afternoon Trading; Oral KRAS G12D Inhibitor Discloses Strong Clinical Data

Stock News10-21 14:38

GENFLEET-B (02595) rose nearly 4% in afternoon trading. As of press time, the stock was up 3.57% at HK$30.76, with a turnover of HK$93.7925 million.

On the news front, GENFLEET-B and Verastem Oncology recently announced positive progress across multiple domestic and overseas clinical studies of the oral KRAS G12D inhibitor GFH375/VS-7375, and released the latest data from the related research, demonstrating favorable efficacy and safety.

China Securities Co., Ltd. released a research report stating that, based on the advancement of the registrational Phase III trial of GFH375 and the expansion into multiple indications and frontline combination therapies, combined with the clinical potential of GFH276, the pipeline layout of GFS202A and GFS784, as well as the progress of overseas development and collaboration, the clinical and commercial prospects of the company's core products are expected to become clearer, providing support for its medium- to long-term development.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment